Menu
GWAS Study

Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes.

Vacic V, Ozelius LJ, Clark LN et al.

24842889 PubMed ID
GWAS Study Type
6630 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

VV
Vacic V
OL
Ozelius LJ
CL
Clark LN
BA
Bar-Shira A
GM
Gana-Weisz M
GT
Gurevich T
GA
Gusev A
KM
Kedmi M
KE
Kenny EE
LX
Liu X
MH
Mejia-Santana H
MA
Mirelman A
RD
Raymond D
SR
Saunders-Pullman R
DR
Desnick RJ
AG
Atzmon G
BE
Burns ER
OH
Ostrer H
HH
Hakonarson H
BA
Bergman A
BN
Barzilai N
DA
Darvasi A
PI
Peter I
GS
Guha S
LT
Lencz T
GN
Giladi N
MK
Marder K
PI
Pe'er I
BS
Bressman SB
OA
Orr-Urtreger A
Chapter II

Abstract

Summary of the research findings

The recent series of large genome-wide association studies in European and Japanese cohorts established that Parkinson disease (PD) has a substantial genetic component. To further investigate the genetic landscape of PD, we performed a genome-wide scan in the largest to date Ashkenazi Jewish cohort of 1130 Parkinson patients and 2611 pooled controls. Motivated by the reduced disease allele heterogeneity and a high degree of identical-by-descent (IBD) haplotype sharing in this founder population, we conducted a haplotype association study based on mapping of shared IBD segments. We observed significant haplotype association signals at three previously implicated Parkinson loci: LRRK2 (OR = 12.05, P = 1.23 × 10(-56)), MAPT (OR = 0.62, P = 1.78 × 10(-11)) and GBA (multiple distinct haplotypes, OR > 8.28, P = 1.13 × 10(-11) and OR = 2.50, P = 1.22 × 10(-9)). In addition, we identified a novel association signal on chr2q14.3 coming from a rare haplotype (OR = 22.58, P = 1.21 × 10(-10)) and replicated it in a secondary cohort of 306 Ashkenazi PD cases and 2583 controls. Our results highlight the power of our haplotype association method, particularly useful in studies of founder populations, and reaffirm the benefits of studying complex diseases in Ashkenazi Jewish cohorts.

1,130 Ashkenazi Jewish cases, 2,611 Ashkenazi Jewish controls

Chapter III

Study Statistics

Key metrics and study information

6630
Total Participants
GWAS
Study Type
Yes
Replicated
306 Ashkenazi Jewish cases, 2,583 Ashkenazi Jewish controls
Replication Participants
Other
Ancestry
U.S., Israel
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.